Global Orphan Drugs Industrial and Market studies Report: 2016 Edition
"Global
Orphan Drugs Market Report: 2016 Edition"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
A
rare disease is the one that occurs uncommonly or rarely in the
general population.
However, there exists no clear definition for
categorizing “rare diseases” and is usually defined on the basis
of the prevalence, and some other factors including the severity of
disease and availability of treatment options. Rare diseases are
often serious, chronic and progressive. Orphan drugs are medicinal
products intended for the diagnosis, prevention or treatment of rare
diseases. These drugs are referred to be “orphan” as under normal
conditions because these drugs are not cost effective to be developed
by the pharmaceuticals industry, intended for a small number of
patients suffering from rare conditions.
Get
Sample
Report
With TOC @
https://www.researchmoz.us/enquiry.php?type=S&repid=548106
Increasing
sales of prescription drugs, substantial benefits for new entrants in
rare disease drug market, increased spending on medicines, rising
healthcare expenditure and improving economic conditions of nations
are some of the significant factors driving growth of the Orphan
drugs market. However, the growth of the market is hindered by
certain challenges including tougher regulatory approvals, limitation
on charging higher prices and no approved drugs for several rare
diseases including Polychethemia Vera (PV).
The global orphan drugs market is expected to see
numerous developments including approval of several Ultra-Rare
drugs, increasing scope of Gene therapy, development of drugs for
rare blood disease, higher success prospects for Hematology compared
to Solid Tumors, attractive pricing option for orphan drug
competitors and striking opportunities in developing orphan drugs.
The report, “Global Orphan Drugs Market”
analyzes the current prevailing condition of the market along with
its future scope of development. The global market along with
specific market of the U.S., Canada, Europe and Japan, is being
discussed in the report. The major trends, growth drivers as well as
issues being faced by the industry are being presented in this
report. The major players in the industry are being profiled, along
with their key financials and strategies for growth.
Table of Content
1. Orphan Diseases: Introduction
1.1 Causes
1.2 Prevention
1.3 Diagnosis
1.4 Treatment Options
1.5 Orphan Drugs
1.1 Causes
1.2 Prevention
1.3 Diagnosis
1.4 Treatment Options
1.5 Orphan Drugs
2. Market Analysis
2.1 Global Orphan Drugs Market
2.1 Global Orphan Drugs Market
- Market Value
- Growth Rate
- Market Segmentation
2.1.1 NonHodgkin’s Lymphoma (NHL) Market
3. Regional Analysis
3.1 The U.S. Orphan Drugs Market
3.1 The U.S. Orphan Drugs Market
- Applications & Designations
- Spending Growth Forecast
3.1.1 The UltraRare Drugs Market
3.2 Canada
3.3 Europe
3.4 Japan
3.2 Canada
3.3 Europe
3.4 Japan
4. Market Dynamics
4.1 Key Trends and Developments
4.1.1 Striking Opportunities in Developing Orphan Drugs
4.1.2 Attractive Pricing Option for Orphan Drug Companies
4.1.3 Higher Success Prospect for Hematology vs. Solid Tumors
4.1.4 Development of Drugs for Rare Blood Diseases
4.1.5 Increasing Scope of Gene Therapy
4.1.6 Approval of UltraOrphan Drugs
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
4.2.2 Substantial Benefits for New Entrants in Rare Diseases Market
4.2.3 Increased Spending on Medicines
4.2.4 Rising Healthcare Expenditure
4.2.5 Rising Global GDP
4.3 Challenges
4.3.1 Limitation on Charging High Price for Orphan Drugs
4.3.2 No Approved Drug for Polycythemia Vera Firstline Treatment
4.3.3 Tough Regulatory Approval for Orphan Drugs
4.1 Key Trends and Developments
4.1.1 Striking Opportunities in Developing Orphan Drugs
4.1.2 Attractive Pricing Option for Orphan Drug Companies
4.1.3 Higher Success Prospect for Hematology vs. Solid Tumors
4.1.4 Development of Drugs for Rare Blood Diseases
4.1.5 Increasing Scope of Gene Therapy
4.1.6 Approval of UltraOrphan Drugs
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
4.2.2 Substantial Benefits for New Entrants in Rare Diseases Market
4.2.3 Increased Spending on Medicines
4.2.4 Rising Healthcare Expenditure
4.2.5 Rising Global GDP
4.3 Challenges
4.3.1 Limitation on Charging High Price for Orphan Drugs
4.3.2 No Approved Drug for Polycythemia Vera Firstline Treatment
4.3.3 Tough Regulatory Approval for Orphan Drugs
5. Competitive Landscape
5.1 Global Market
5.1 Global Market
- Market Share
- Product Comparison
5.2 The U.S. Market
- Market Share
- Product Comparison
6. Company Profiles
6.1 Roche Holdings
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Celgene Corporation
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.1 Roche Holdings
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Celgene Corporation
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
Comments
Post a Comment